Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RONALD PAQUETTE

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1992725576
CMS profile
362672
Location
LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$9,071.57

12 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $8,410.00 3
Food and Beverage $661.57 9

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Novartis Pharmaceuticals Corporation $5,056.56 6
Alexion Pharmaceuticals, Inc. $3,641.48 2
PFIZER INC. $121.81 1
E.R. Squibb & Sons, L.L.C. $120.90 1
ABBVIE INC. $105.90 1
Incyte Corporation $24.92 1

Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RONALD PAQUETTE

NPI 1992725576 · CMS profile ID 362672

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1992725576?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RONALD PAQUETTE, NPI 1992725576, CMS profile ID 362672. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1992725576?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). RONALD PAQUETTE, NPI 1992725576, CMS profile ID 362672. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1992725576?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
RONALD PAQUETTE, NPI 1992725576, CMS profile ID 362672, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1992725576?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

12 matching records · $9,071.57 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 12 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–12 of 12.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $3.7511/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200621605 CMS
Novartis Pharmaceuticals Corporation $1,050.0011/03/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1200621611 CMS
E.R. Squibb & Sons, L.L.C. $120.9009/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184918918 CMS
ABBVIE INC. $105.9008/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1203458834 CMS
Novartis Pharmaceuticals Corporation $19.7708/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200758421 CMS
Alexion Pharmaceuticals, Inc. $131.4807/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202937222 CMS
Alexion Pharmaceuticals, Inc. $3,510.0007/04/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1202986648 CMS
Novartis Pharmaceuticals Corporation $3,850.0006/20/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1200621589 CMS
Novartis Pharmaceuticals Corporation $37.2005/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200758413 CMS
Novartis Pharmaceuticals Corporation $95.8402/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200758399 CMS
Incyte Corporation $24.9202/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226133339 CMS
PFIZER INC. $121.8102/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228875322 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $580.48 12
PY2020 $2,822.31 5
PY2021 $4,601.85 3
PY2022 $5,876.25 9
PY2023 $496.63 6
PY2024 $1,243.84 10
PY2025 $9,071.57 12

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2023 Principal investigator $58.54 1
PY2022 Principal investigator $5,030.70 3
PY2021 Principal investigator $22,436.65 11
PY2020 Principal investigator $127,651.02 17
PY2019 Recipient $409.50 1
PY2019 Principal investigator $51,400.40 20

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

17 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Celgene Corporation $6,500.00 08/31/2020 Covered Recipient Teaching Hospital
Cedars-Sinai Medical Center
A SAFETY TRIAL OF LISOCABTAGENE MARALEUCEL (JCAR01 No dispute reported 06/30/2026 753808093
Principal investigator 1 Celgene Corporation $7,410.00 08/31/2020 Covered Recipient Teaching Hospital
Cedars-Sinai Medical Center
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting No dispute reported 06/30/2026 753808321
Principal investigator 1 Incyte Corporation $360.00 06/18/2020 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
An Open Label Assessment of Safety and Efficacy of Ruxolitinib, INCB018424, in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia myelofibrosis and Post Polycythemia Vera myelofibrosis Who Have Platelet Counts of 50 times 10 to the power of 9 per L to 100 times 10 to the power of 9 per L No dispute reported 06/30/2026 744298581
Principal investigator 1 Incyte Corporation $6,366.40 06/18/2020 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
An Open Label Assessment of Safety and Efficacy of Ruxolitinib, INCB018424, in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia myelofibrosis and Post Polycythemia Vera myelofibrosis Who Have Platelet Counts of 50 times 10 to the power of 9 per L to 100 times 10 to the power of 9 per L No dispute reported 06/30/2026 744298583
Principal investigator 1 Alexion Pharmaceuticals, Inc. $393.50 06/11/2020 Covered Recipient Teaching Hospital
Cedars-Sinai Medical Center
A Phase III randomized, open-label, active-controlled study of ALXN1210 versus eculizumab in complement inhibitor naive adult patients with PNH No dispute reported 06/30/2026 724602099
Principal investigator 1 Alexion Pharmaceuticals, Inc. $910.00 06/11/2020 Covered Recipient Teaching Hospital
Cedars-Sinai Medical Center
A Phase III randomized, open-label, active-controlled study of ALXN1210 versus eculizumab in complement inhibitor naive adult patients with PNH No dispute reported 06/30/2026 724602111
Principal investigator 1 Alexion Pharmaceuticals, Inc. $975.00 06/11/2020 Covered Recipient Teaching Hospital
Cedars-Sinai Medical Center
A Phase III randomized, open-label, active-controlled study of ALXN1210 versus eculizumab in complement inhibitor naive adult patients with PNH No dispute reported 06/30/2026 724602117
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,500.00 05/22/2020 Covered Recipient Teaching Hospital
CEDARS-SINAI MEDICAL CENTER
A PHASE 3, RANDOMIZED, CONTROLLED, OPEN-LABEL, MULTICENTER, SAFETY AND EFFICACY STUDY OF DEXAMETHASONE PLUS MLN9708 OR PHYSICIANS CHOICE OF TREATMENT ADMINISTERED TO PATIENTS WITH RELAPSED OR REFRACTORY SYSTEMIC LIGHT CHAIN (AL) AMYLOIDOSIS No dispute reported 06/30/2026 737060469
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $188.00 05/22/2020 Covered Recipient Teaching Hospital
CEDARS-SINAI MEDICAL CENTER
A PHASE 3, RANDOMIZED, CONTROLLED, OPEN-LABEL, MULTICENTER, SAFETY AND EFFICACY STUDY OF DEXAMETHASONE PLUS MLN9708 OR PHYSICIANS CHOICE OF TREATMENT ADMINISTERED TO PATIENTS WITH RELAPSED OR REFRACTORY SYSTEMIC LIGHT CHAIN (AL) AMYLOIDOSIS No dispute reported 06/30/2026 737060471
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $938.00 05/22/2020 Covered Recipient Teaching Hospital
CEDARS-SINAI MEDICAL CENTER
A PHASE 3, RANDOMIZED, CONTROLLED, OPEN-LABEL, MULTICENTER, SAFETY AND EFFICACY STUDY OF DEXAMETHASONE PLUS MLN9708 OR PHYSICIANS CHOICE OF TREATMENT ADMINISTERED TO PATIENTS WITH RELAPSED OR REFRACTORY SYSTEMIC LIGHT CHAIN (AL) AMYLOIDOSIS No dispute reported 06/30/2026 737060473
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $2,302.70 05/20/2020 Covered Recipient Teaching Hospital
Cedars-Sinai Medical Center
PCYC-1123-CA No dispute reported 06/30/2026 727731505
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $715.52 05/12/2020 Covered Recipient Teaching Hospital
Cedars-Sinai Medical Center
PCYC-1123-CA No dispute reported 06/30/2026 727731517
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $13,228.90 05/06/2020 Covered Recipient Teaching Hospital
Cedars-Sinai Medical Center
Phase IIB Hodgkins Lymphoma No dispute reported 06/30/2026 736758381
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $136.50 04/28/2020 Covered Recipient Teaching Hospital
CEDARS-SINAI MEDICAL CENTER
A PHASE 3, RANDOMIZED, CONTROLLED, OPEN-LABEL, MULTICENTER, SAFETY AND EFFICACY STUDY OF DEXAMETHASONE PLUS MLN9708 OR PHYSICIANS CHOICE OF TREATMENT ADMINISTERED TO PATIENTS WITH RELAPSED OR REFRACTORY SYSTEMIC LIGHT CHAIN (AL) AMYLOIDOSIS No dispute reported 06/30/2026 737060457
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $2,347.00 04/21/2020 Covered Recipient Teaching Hospital
Cedars-Sinai Medical Center
PCYC-1123-CA No dispute reported 06/30/2026 727731509
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $81,671.20 03/22/2020 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
Open-Label Single Arm Phase 2 Study Evaluating Dasatinib Therapy Discontinuation In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) With Stable Complete Molecular Response (CMR) DASFREE No dispute reported 06/30/2026 736756721
Principal investigator 1 Alexion Pharmaceuticals, Inc. $708.30 01/02/2020 Covered Recipient Teaching Hospital
Cedars-Sinai Medical Center
A Phase III randomized, open-label, active-controlled study of ALXN1210 versus eculizumab in complement inhibitor naive adult patients with PNH No dispute reported 06/30/2026 724602105